Share on LinkedInShare on LinkedIn

ARTICLE · 09 JUNE 2016

Teva Api India Pvt. Ltd. & Anr. Vs. Merck Sharp & Dohme Corp & Anr.

S.S. Rana & Co.
S.S. Rana & Co.
Contributor
S.S. Rana & Co.

S.S. Rana & Co.

Established in 1989, S.S. Rana & Co. is a premier intellectual property and corporate law firm...

View firm profile
Explore more from S.S. Rana & Co.

In a recent patent infringement case Teva Api India Pvt. Ltd. & Anr. v. Merck Sharp & Dohme Corp & Anr. FAO (OS) (COMM) 34/2016, the Division Bench of the Delhi High Court vide its order dated May 30, 2016.

IndiaIntellectual Property

In a recent patent infringement case Teva Api India Pvt. Ltd. & Anr. v. Merck Sharp & Dohme Corp & Anr. FAO (OS) (COMM) 34/2016, the Division Bench of the Delhi High Court vide its order dated May 30, 2016 dealt with the issue of expeditious hearing and disposal of applications seeking vacation of ex-parte ad interim injunctions within 30 days, as stipulated by the Indian Code of Civil Procedure, 1908

BRIEF FACTS:

  • The respondents originally sued the appellants alleging infringement of their rights flowing from Indian Patent No. 209816 concerning a molecule having an International No-proprietary Name, SITAGLIPTIN. It was the case of the respondents that the combination of Sitagliptin and another drug known as Metformin HCL is sold under the trademark JANUMET, while stand-alone Sitagliptin was sold under the trademark JANUVIA. The respondents alleged that the appellants are manufacturing and selling its patented product.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from